Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

lynparza

AstraZeneca and MSD’s Lynparza crosses superiority boundary for invasive disease-free survival

February 17, 2021 Research and Development AstraZeneca, Cancer, MSD

The OlympiA Phase III trial for AstraZeneca and MSD’s cancer drug Lynparza will move to early primary analysis and reporting, …
News

Novartis and Gates Foundation join forces on sickle cell disease research

February 17, 2021 Research and Development Novartis, sickle cell disease

Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation, under which the foundation will fund …
News

FDA approves Novartis’ heart failure drug Entresto

February 17, 2021 Research and Development FDA, Novartis

The FDA has approved Novartis’ Entresto (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalisation for heart failure in …
News
elizabeth_crain

Exscientia appoints Moelis & Company COO Elizabeth Crain to Board of Directors

February 10, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

AI-driven pharma-tech company Exscientia has appointed Elizabeth Crain to their Board of Directors.
Appointment

Accure Therapeutics’ drug candidate can slow epilepsy progression, study shows

February 10, 2021 Research and Development epilepsy

Accure Therapeutics, an R&D pharmaceutical company in the central nervous system (CNS) field, has announced the publication of a pivotal …
News
covid_cell_1_20

Pharmafile.com’s weekly COVID-19 news round-up

February 10, 2021 Research and Development COVID-19

The past week has seen lots of positive COVID-19 vaccine news; Oxford University and AstraZeneca have announced development of another …
News
astrazeneca_sign_sky

South Korea approves AstraZeneca COVID-19 vaccine for use

February 10, 2021 Research and Development AstraZeneca, COVID-19

South Korea is to grant first approval for the Oxford University-AstraZeneca vaccine later today, with the rollout expected to start …
News
fdaoutsideweb

FDA approves Sanofi’s Libtayo for advanced basal cell carcinoma

February 10, 2021 Research and Development Cancer, FDA, Sanofi

The FDA has approved Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell …
News
janssen_latest_logo_on_sign

Janssen announces positive Phase III results for prostate cancer drug apalutamide

February 10, 2021 Research and Development Cancer, Janssen

Final results from Janssen’s Phase III TITAN study have shown its cancer drug apalutamide improved overall survival (OS) in patients …
News
mark_wilcox_002

Destiny Pharma appoints Professor Mark Wilcox to its Scientific Advisory Board

February 4, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Destiny Pharma, a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening …
Appointment
caroline_oconnor

Raremark appoints Caroline O’Connor as CCO

February 4, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Raremark has appointed Caroline O’Connor as its new Chief Commercial Officer. Previously holding the position of Raremark’s Senior Vice President …
Appointment
covid_cell_1_20

Pharmafile.com’s weekly COVID-19 news round-up

February 3, 2021 Research and Development COVID-19

The past week has seen mostly positive COVID-19 vaccine developments; Pfizer has confirmed its jab is effective against both the …
News
astrazeneca_sign_sky

Longer Oxford-AstraZeneca vaccine interval improves efficacy, report says

February 3, 2021 Research and Development AstraZeneca, COVID-19

A longer interval between doses of the Oxford University-AstraZeneca vaccine could substantially improve efficacy, according to a report published in …
News

GSK and CureVac sign £132m deal to develop next-generation COVID-19 vaccine

February 3, 2021 Research and Development COVID-19, CureVac, GlaxoSmithKline

GlaxoSmithKline (GSK) and CureVac have today announced they are joining forces to develop a new COVID-19 vaccine to combat future …
News
stock-incyte-01-shutter

CHMP recommends marketing authorisation for Incyte’s pemigatinib

February 3, 2021 Research and Development EMA, Incyte

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the conditional marketing authorisation of Incyte’s pemigatinib for …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026